THE WOODLANDS, Texas--(BUSINESS WIRE)--Fuzionaire Theranostics, Inc. (“Fuzionaire Tx”) announced today that Li Boynton and Klaus Kopka, PhD have joined the company’s Board of Directors and Advisory Board, respectively, supporting the company’s growth into clinical development.

德克萨斯州伍德兰市——（商业新闻短讯）——Fuzionaire Theranostics，Inc.（“Fuzionaire Tx”）今天宣布，Li Boynton和Klaus Kopka博士分别加入了该公司的董事会和顾问委员会，支持该公司向临床开发的发展。

Ms. Boynton joins the Board of Directors following a decade in healthcare finance. She was most recently a biopharma equity analyst at JPMorgan Asset Management, one of the largest investment platforms in biopharma globally, where she spent over six years investing in biotechnology, pharmaceuticals, and specialty pharmaceuticals across a broad range of US portfolios.

博因顿女士在从事医疗保健金融十年后加入董事会。最近，她是摩根大通资产管理公司（JPMorgan Asset Management）的生物制药股票分析师。摩根大通资产管理公司是全球最大的生物制药投资平台之一，她在那里花了六年多的时间，在美国的各种投资组合中投资生物技术、制药和特种制药。

Previously, Ms. Boynton held investment roles at Guggenheim Partners and Healthcare Royalty Partners following undergraduate immunology and proteomics research at Yale, where she completed her B.S. in Molecular, Cellular and Developmental Biology..

此前，博因顿女士在耶鲁大学完成了免疫学和蛋白质组学的本科研究，并在古根海姆合作伙伴和医疗保健皇室合作伙伴担任投资角色，在那里她完成了分子、细胞和发育生物学的学士学位。。

Dr. Kopka joins the Advisory Board as a full professor in Bioinorganic and Radiopharmaceutical Chemistry at Technical University Dresden, Germany, and Director of the Institute of Radiopharmaceutical Cancer Research, HZDR, Germany. Previously, he held a full professorship at Ruprecht-Karls-University of Heidelberg and was head of the Division of Radiopharmaceutical Chemistry at the German Cancer Research Center, DKFZ, in Heidelberg..

Kopka博士加入咨询委员会，担任德国德累斯顿工业大学生物无机和放射性药物化学的全职教授，以及德国HZDR放射性药物癌症研究所所长。此前，他在海德堡鲁普雷希特·卡尔斯大学（Ruprecht Karls University of Heidelberg）担任全职教授，并担任海德堡德国癌症研究中心（DKFZ）放射性药物化学部门负责人。。

Dr. Kopka is a co-inventor of fluorine-18-PSMA-1007, or Radelumin®, and lutetium-177-PSMA-617, or Pluvicto®. Novartis’s Pluvicto, for patients with PSMA+ metastatic castration-resistant prostate cancer (mCRPC), is the first and to date only approved PSMA-targeted radioligand therapy.

Kopka博士是氟-18-PSMA-1007或Radelumin®和lutetium-177-PSMA-617或Pluvicto®的共同发明者。诺华的Pluvicto针对PSMA+转移性去势抵抗性前列腺癌（mCRPC）患者，是第一个也是迄今为止唯一批准的PSMA靶向放射性配体治疗。

Fuzionaire Tx adds Ms. Boynton’s experience in financial markets and investing in public and private biopharmaceutical companies, and Dr. Kopka’s expertise in radiopharmaceuticals in clinical and academic settings prior to commercial launches, as the company’s GRPR-targeting radiopharmaceuticals advance into first-in-patient tests at medical centers in Germany..

Fuzionaire Tx增加了Boynton女士在金融市场和投资公共和私人生物制药公司方面的经验，以及Kopka博士在商业推出之前在临床和学术环境中的放射性药物方面的专业知识，因为该公司针对放射性药物的GRPR进入了德国医疗中心的首次患者测试。。

Supporting the company’s GRPR-focused research and development, collaborators of Fuzionaire Tx at McGill University and McMaster University have been awarded a grant from the Canadian Institutes of Health Research (CIHR). The grant will expand the company’s developmental work on GRPR-targeting theranostic radiopharmaceuticals using the HetSiFA® platform..

为支持该公司以GRPR为重点的研究和开发，麦吉尔大学和麦克马斯特大学的Fuzionaire Tx合作者获得了加拿大卫生研究院（CIHR）的资助。该赠款将扩大该公司使用HetSiFA®平台针对治疗诊断放射性药物的GRPR开发工作。。

The company’s heteroaromatic silicon-fluoride acceptors, or HetSiFAs, are modular radiolabeling moieties that enable rapid prototyping of peptide-based theranostics, tunable albumin binding to optimize biodistribution, manufacture of fluorine-18 PET companions at large scale, and chemically identical therapeutic and diagnostic pairs.

该公司的杂芳族氟化硅受体或HetSiFAs是模块化的放射性标记部分，能够快速原型化基于肽的治疗学，可调白蛋白结合以优化生物分布，大规模制造氟-18 PET伴侣，以及化学上相同的治疗和诊断对。

The company’s HetSiFA-based radioligand therapies use actinium-225 and other leading alpha- and beta-emitting radionuclides..

该公司基于HetSiFA的放射性配体疗法使用锕225和其他主要的α和β放射性核素。。

About Fuzionaire Theranostics

关于Fuzionaire Theranostics

Fuzionaire Theranostics is a radiopharmaceutical company on a mission to make better and more accessible theranostic treatments for people with cancer. With origins in Nobel laureate Robert Grubbs' lab at Caltech, the company's patented HetSiFA® platform enables rapid development of radioligand therapies and companion PET diagnostics, and offers manufacturing advantages in a clinical setting.

Fuzionaire Theranostics是一家放射性制药公司，其使命是为癌症患者提供更好，更容易获得的治疗方法。该公司拥有专利的HetSiFA®平台起源于加州理工学院诺贝尔奖获得者罗伯特·格拉布斯的实验室，能够快速开发放射性配体疗法和伴随的PET诊断，并在临床环境中提供制造优势。

The company’s pipeline addresses pressing clinical needs for several types of cancer, beginning with cancers in which gastrin-releasing peptide receptor (GRPR) is expressed, including metastatic prostate cancer..

该公司的管道解决了几种癌症的迫切临床需求，首先是表达胃泌素释放肽受体（GRPR）的癌症，包括转移性前列腺癌。。

For more, visit us at: www.fuzionairetx.com

如需更多信息，请访问我们的网站：www.fuzionairetx.com